tetano
Editor, Senior Moderator
Int J Cardiol
. 2020 Jul 29;S0167-5273(20)33526-9.
doi: 10.1016/j.ijcard.2020.07.041. Online ahead of print.
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
Massimo Volpe[SUP] 1 [/SUP], Allegra Battistoni[SUP] 2 [/SUP]
Affiliations
Abstract
A role for the renin-angiotensin-aldosterone-system in Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. Even though a suggestive pathophysiological link between renin-angiotensin-aldosterone-system and the virus has been proposed, its pathogenic role remains very difficult to be defined. Although COronaVIrus Disease-19 targets preferentially older people with high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. In this article, we scrutinize evidence from the most representative available studies in which the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, was evaluated in the COronaVIrus Disease-19 disease course, with regard to severity of the disease and mortality. We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted.
Keywords: Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; Covid-19; Hypertension; Renin-angiotensin-aldosterone system.
. 2020 Jul 29;S0167-5273(20)33526-9.
doi: 10.1016/j.ijcard.2020.07.041. Online ahead of print.
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
Massimo Volpe[SUP] 1 [/SUP], Allegra Battistoni[SUP] 2 [/SUP]
Affiliations
- PMID: 32738257
- DOI: 10.1016/j.ijcard.2020.07.041
Abstract
A role for the renin-angiotensin-aldosterone-system in Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. Even though a suggestive pathophysiological link between renin-angiotensin-aldosterone-system and the virus has been proposed, its pathogenic role remains very difficult to be defined. Although COronaVIrus Disease-19 targets preferentially older people with high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. In this article, we scrutinize evidence from the most representative available studies in which the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, was evaluated in the COronaVIrus Disease-19 disease course, with regard to severity of the disease and mortality. We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted.
Keywords: Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; Covid-19; Hypertension; Renin-angiotensin-aldosterone system.